Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and/or Cabozantinib in 2nd/3rd Line EGFR Wild-Type NSCLC
NCT01708954Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, erlotinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Feb 2013; status: active, not recruiting.
02
Drugs
cabozantiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01708954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708954.